About C4 Therapeutics
C4 Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2016 by Marc A Cohen. Small-molecule drugs for cancer treatment are developed via Degronimid platform. C4 Therapeutics has raised $223 million across 4 funding rounds from investors including Novartis, Janus Henderson Investors and RTW Investments. The company has 110 employees. C4 Therapeutics offers products and services including Cemsidomide, CFT1946, and CFT8919. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is C4 Therapeutics, Inc. Its competitors include Erasca, MiRagen and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
C4 Therapeutics was established in 2016 and is based in Cambridge, United States. Focus is placed on the biotechnology sector, where small-molecule therapeutics are created to address cancer. The Degronimid platform is employed to design binders that selectively target problematic proteins, enabling their degradation through the cellular proteasome pathway. Development efforts include CFT7455 aimed at hematologic malignancies, CFT8634 for sarcoma, and a BRAF V600E inhibitor for solid tumors.
- Headquarters Cambridge, United States
- Employees 110
- Founders Marc A Cohen
- Stage Public
- SectorsHealthcare
- Website c4therapeutics.com
- Social LinkedIn X
- Legal Name C4 Therapeutics, Inc.
- Annual Revenue$35.95 M (USD)1.02as on Dec 31, 2025
- Net Profit-$104.99 M (USD)0.31as on Dec 31, 2025
- EBITDA-$96.51 M (USD)11.68as on Dec 31, 2025
- Total Equity Funding$223M (USD)
in 4 rounds
- Latest Funding Round$25M (USD), Post-IPO
Jan 2024
- InvestorsNovartis
& 23 more
- Employee Count110
Products & Services of C4 Therapeutics
C4 Therapeutics offers a comprehensive portfolio of products and services, including Cemsidomide, CFT1946, and CFT8919.
Therapy that degrades proteins to treat diseases.
Protein degradation treatment for targeted medical applications.
Innovative drug using protein degradation for disease management.
Funding Insights of C4 Therapeutics
C4 Therapeutics has successfully raised a total of $223M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $223M
- Total Rounds 4
- Last Round Post-IPO — $25M
- First Round $73M
(Jan 2016)
- Investors Count 24
All 4 funding rounds of C4 Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $25M | Post-IPO | – | – | |
| Jun 2020 | $20M | Debt – Venture | – | – | |
| Jun 2020 | $150M | Series B | – | Cobro Ventures, Perceptive Advisors | |
| Jan 2016 | $73M | Series A | – | Cobro Ventures |
24 investors in total: 24 institutional.
Investors in C4 Therapeutics
C4 Therapeutics has secured backing from 24 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Janus Henderson Investors and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Investment firm backed by the Cohen family | cobroventures.com | Mclean, United States | ||
Early-stage investments are targeted by Axil Capital, a VC firm. | axilcapital.com | Minato City, Japan | ||
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Tech & Life Science focused early & growth stage VC firm investing in the US & China | 3ebiovc.com | Beijing, China | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private fund focused on debt, equity, and real estate investments | ms-pi.com | Chiyoda City, Japan |
Investor details for C4 Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of C4 Therapeutics
65 people are tracked at C4 Therapeutics (36 in leadership, 17 in board & advisors, 12 in team); the tracked headcount is 110.
| Name | Role | Group |
|---|---|---|
Marc A Cohen | Co-Founder | Leadership |
Andrew Hirsch | President & CEO | Leadership |
Mayra Reyes-Armour | VP, Technical Operations | Leadership |
Robert Bruno | Vice President, CMC And Supply Chain | Leadership |
Scott Boyle | Chief Business Officer | Leadership |
Len Reyno | Chief Medical Officer | Leadership |
Kelly Schick | Chief People Officer | Leadership |
Jolie Siegel | Chief Legal Officer | Leadership |
Loraine Spreen | Senior Director, Corporate Communications & Patient Advocacy | Leadership |
Melissa Epstein | Director, Total Rewards | Leadership |
Jiannan Henry Lu | Director, Formulation | Leadership |
Dina Minerd | Sr. Director, Human Resources Business Partner | Leadership |
Matthew Forti | Head Of Facilities | Leadership |
Roy Pollock | Senior Vice President, Biological Sciences | Leadership |
Riadh Lobbardi | Senior Director, Translational Medicine | Leadership |
Brent Appleton | Senior Director | Leadership |
Justine Rovedo | Chief Of Staff To CEO | Leadership |
Amy Seidel | Senior Director Drug Safety And Pharmacovigilance | Leadership |
Shagha Russell | Vice President, Deputy General Counsel | Leadership |
Katelyn Cassidy | Associate Director Of Proteomics | Leadership |
45 more people are available in the full profile.
Complete people profiles for C4 Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of C4 Therapeutics
C4 Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CCCC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Oct 2020
- Listed onNASDAQ: CCCC
- Listed entityC4 Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS12529R1077
- Share price$2.78 (-9.15% on the day) · 2026-10-13
- Market capitalisation$342.0M
- EPS (diluted, trailing year)$-1.00
- Volume (last session)3,821,394
Financials of C4 Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $36.0M | -$105.0M | -$96.5M |
| 2024 | $35.6M | -$105.3M | -$109.3M |
| 2023 | $20.8M | -$132.5M | -$131.3M |
| 2022 | $31.1M | -$128.2M | -$122.0M |
| 2021 | $45.8M | -$83.9M | -$79.2M |
Detailed financial statements for C4 Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of C4 Therapeutics
4 dated milestones of C4 Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded C4 Therapeutics is founded.
- Funding First funding round of $73.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
Competitors of C4 Therapeutics
C4 Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Erasca, MiRagen and Nimbus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of C4 Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of C4 Therapeutics
The website of C4 Therapeutics (c4therapeutics.com) receives about 9.3K visits a month.
- Monthly visits9.3K
▲ 16.9% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as C4 Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about C4 Therapeutics
Complete news archive for C4 Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C4 Therapeutics
C4 Therapeutics was founded in 2016.
C4 Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
C4 Therapeutics is a funded company, having raised a total of $223M across 4 funding rounds to date. The company's 1st funding round was a Series A of $73M, raised on Jan 2016.
C4 Therapeutics has 110 employees.
Annual revenue of C4 Therapeutics is $35.95M as on Dec 31, 2025.
C4 Therapeutics was established in 2016 and is based in Cambridge, United States. Focus is placed on the biotechnology sector, where small-molecule therapeutics are created to address cancer. The Degronimid platform is employed to design binders that selectively target problematic proteins, enabling their degradation through the cellular proteasome pathway. Development efforts include CFT7455 aimed at hematologic malignancies, CFT8634 for sarcoma, and a BRAF V600E inhibitor for solid tumors.
C4 Therapeutics's top competitors include Erasca, Nimbus Therapeutics and MiRagen.
C4 Therapeutics offers Cemsidomide, CFT1946, and CFT8919.
Yes, C4 Therapeutics is publicly traded on NASDAQ under the ticker symbol CCCC.
C4 Therapeutics has 24 investors. Key investors include Novartis, Janus Henderson Investors, RTW Investments, RA Capital, and Perceptive Advisors.
C4 Therapeutics operates through C4 Therapeutics, Inc..